Orexigen obesity med faces uphill fight--and that's if it's approved

If Orexigen wins FDA approval for its new weight loss drug, how will it and its pharma partner Takeda take on the obesity market? After all, it's an area where two recent debuts are struggling for recognition. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.